Wolman Disease

Also known as: Lysosomal acid lipase deficiency, LAL-D

What is it?

Wolman disease is a severe lysosomal storage disorder caused by a deficiency of the enzyme lysosomal acid lipase (LAL). This enzyme is responsible for breaking down cholesteryl esters and triglycerides into free cholesterol and fatty acids. The disorder results from mutations in the LIPA gene. When LAL is absent or severely reduced, fats accumulate rapidly in cells of the liver, spleen, adrenal glands, intestines, and bone marrow, leading to widespread organ dysfunction. Wolman disease represents the most severe end of the lysosomal acid lipase deficiency spectrum.

How common is it?

Wolman disease is extremely rare. The exact prevalence is unknown, but estimates suggest 1 in 40,000 to 300,000 births, depending on population. Males and females are affected equally.

Signs & Symptoms

Symptoms usually appear within the first weeks or months of life and progress rapidly. Infants commonly develop: • Failure to thrive • Chronic diarrhea and vomiting • Poor absorption of nutrients • Severe weight loss Other features include: • Massive enlargement of the liver and spleen • Liver failure and jaundice • Calcification of the adrenal glands (a hallmark finding) • Anemia and thrombocytopenia • Progressive multi-organ failure Without treatment, most infants do not survive beyond the first year of life.

Causes & Inheritance

Wolman disease is caused by mutations in the LIPA gene.

Wolman disease is caused by mutations in the LIPA gene. It follows an autosomal recessive inheritance pattern. Both parents must be carriers for a child to be affected.

Diagnosis

Diagnosis is based on: • Clinical presentation • Enzyme assays showing absent or severely reduced LAL activity • Genetic testing • Imaging studies showing adrenal calcifications Early diagnosis is critical for treatment initiation.

Treatment

Treatment options include: • Enzyme replacement therapy (sebelipase alfa) • Nutritional and supportive care • Management of liver disease and metabolic complications ERT has significantly improved survival and outcomes in affected infants.

Disclaimer: The information provided here is for educational purposes only and should not be taken as medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment. Information sourced from reliable medical databases.

Beyond Wolman Disease: The Rare Disease Landscape

While Wolman Disease has its unique clinical manifestations and genetic triggers, most Lysosomal Storage Disorders (LSDs) share a common biological mechanism: the accumulation of cellular waste due to enzyme deficiency.

In the Indian context, the diagnostic odyssey for rare genetic conditions often spans several years, involving multiple medical specialists before a definitive diagnosis is reached. Taraasha Foundation is committed to simplifying this journey through education and specialized support.

We advocate for early clinical intervention and universal newborn screening to detect these conditions before the onset of irreversible symptoms. Understanding the inheritance patterns and the biological basis of metabolic shifts is a vital step for affected families.

Through Enzyme Replacement Therapy (ERT) and emerging gene therapies, the goal of modern medicine remains the same: ensuring a sustainable quality of life and empowering patients to lead fulfilling lives despite their diagnosis.